Immutep Ltd ADR (IMMP)

$1.63 -0.06 (-3.55%)
Market Cap 246.81M
Revenue (ttm) 5.14M
Net Income (ttm) -28.01M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -544.94%
Debt to Equity Ratio 0.01
Volume 58,300
Avg Vol 345,504
Day's Range N/A - N/A
Shares Out 146.04M
Stochastic %K 0%
Beta 1.71
Analysts Strong Sell
Price Target $9.50

Company Profile

Immutep Limited, a late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alpha (efti or IMP321), a soluble LAG-3lg fusion based, which is in clinical development for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 2 8315 7003
Fax: 61 2 8569 1880
Address:
Australia Square, Level 32 264 George Street, Sydney, Australia
IFeelLike
IFeelLike Jul. 15 at 9:04 PM
$IMMP nice, as Marc says, tacti004, if succesfull will enter a market worth 24 billion dollars, and is expected to increase the company value between 10-30x. As said before, will sell my first 1k reaching 30 dollars. Staying patient.
0 · Reply
IFeelLike
IFeelLike Jul. 15 at 8:58 PM
$IMMP
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jul. 15 at 8:32 PM
$IMMP resigns?? No 👎 of course … “Great “ trend from years Disappointed
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jul. 15 at 8:02 PM
$IMMP $JSPR shareholders are Waiting for massive resigns !!
0 · Reply
usera123
usera123 Jul. 15 at 7:50 PM
$IMMP Seeing new bozos arriving. 10 bucks says they're gone in a month, we longs know what too expect here. Nothing at all. The enthusiasm they show will fade along with their positions. Do yourselves a favor new arrivals and sell now. The permabulls are full of shit, as is the BoD and especially the CEO.
1 · Reply
Messerschmittbf109
Messerschmittbf109 Jul. 15 at 6:53 PM
$JSPR $IMMP These board .. awful board Must go home !
0 · Reply
NOCKNOCK
NOCKNOCK Jul. 15 at 6:44 PM
$IMMP suck um up! Ladies and Gentlemen. 😘🤙
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jul. 15 at 2:42 PM
$JSPR all bio up except these $NGNE $INKT $IMMP $JSPR Jasper the worst ..and all board is on the chair 🤮
0 · Reply
Biotechnicity
Biotechnicity Jul. 15 at 1:09 PM
$IMMP This will rise steadily over the next three months or so. An active equity is on the way. Just watch!
1 · Reply
rispi
rispi Jul. 14 at 7:52 PM
$IMMP Last poor fireworks before next offering.
2 · Reply
Latest News on IMMP
Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

May 27, 2025, 8:00 AM EDT - 7 weeks ago

Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo

May 15, 2025, 3:50 PM EDT - 2 months ago

Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo

Immutep Limited: Surging On Positive Head And Neck Data

May 8, 2025, 8:46 AM EDT - 2 months ago

Immutep Limited: Surging On Positive Head And Neck Data

Immutep to Participate in Upcoming Investor Conferences

Apr 2, 2025, 8:00 AM EDT - 3 months ago

Immutep to Participate in Upcoming Investor Conferences

Immutep Quarterly Activities Report Q2 FY25

Jan 31, 2025, 8:00 AM EST - 5 months ago

Immutep Quarterly Activities Report Q2 FY25

Immutep Limited: Continuing To Make The Case For Eftilagimod

Jan 28, 2025, 4:37 PM EST - 6 months ago

Immutep Limited: Continuing To Make The Case For Eftilagimod

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

Dec 17, 2024, 8:00 AM EST - 7 months ago

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

Dec 12, 2024, 8:15 AM EST - 7 months ago

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients

Nov 15, 2024, 3:18 PM EST - 8 months ago

Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients

Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial

Nov 14, 2024, 11:16 AM EST - 8 months ago

Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial

Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

Nov 14, 2024, 8:15 AM EST - 8 months ago

Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

Immutep Quarterly Activities Report Q1 FY25

Oct 29, 2024, 8:00 AM EDT - 9 months ago

Immutep Quarterly Activities Report Q1 FY25

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 10, 2024, 8:00 AM EDT - 9 months ago

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

Immutep: Navigating The Bumps In The Road

Oct 7, 2024, 9:10 AM EDT - 10 months ago

Immutep: Navigating The Bumps In The Road

Immutep's Efti in Combination with MSD's KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer

Sep 16, 2024, 8:00 AM EDT - 10 months ago

Immutep's Efti in Combination with MSD's KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer

Immutep Quarterly Activities Report Q4 FY24

Jul 31, 2024, 8:00 AM EDT - 1 year ago

Immutep Quarterly Activities Report Q4 FY24

Immutep: Positive Efti Treatment Data Leads To Late-Stage Programs

Jul 15, 2024, 1:54 PM EDT - 1 year ago

Immutep: Positive Efti Treatment Data Leads To Late-Stage Programs

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression

Jul 11, 2024, 6:40 PM EDT - 1 year ago

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression

Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results

Jul 3, 2024, 8:00 AM EDT - 1 year ago

Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results

Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer

Jun 25, 2024, 8:00 AM EDT - 1 year ago

Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer

Immutep successfully completes institutional placement and institutional component of entitlement offer

Jun 5, 2024, 6:00 AM EDT - 1 year ago

Immutep successfully completes institutional placement and institutional component of entitlement offer

Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial

Jun 2, 2024, 8:38 PM EDT - 1 year ago

Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial

Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024

May 15, 2024, 8:00 AM EDT - 1 year ago

Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024

Positive Initial Clinical Data Reported from Immutep's Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

May 2, 2024, 8:00 AM EDT - 1 year ago

Positive Initial Clinical Data Reported from Immutep's Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

Immutep: Realizing The Expected Catalysts, With More To Come

May 1, 2024, 12:39 PM EDT - 1 year ago

Immutep: Realizing The Expected Catalysts, With More To Come

Immutep Quarterly Activities Report Q3 FY24

Apr 29, 2024, 8:00 AM EDT - 1 year ago

Immutep Quarterly Activities Report Q3 FY24

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Apr 24, 2024, 8:00 AM EDT - 1 year ago

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

Apr 18, 2024, 8:00 AM EDT - 1 year ago

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Apr 17, 2024, 8:00 AM EDT - 1 year ago

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Announces First Clinical Data from 90mg Dosing of Efti

Mar 5, 2024, 8:00 AM EST - 1 year ago

Immutep Announces First Clinical Data from 90mg Dosing of Efti

Immutep Quarterly Activities Report Q2 FY24

Jan 30, 2024, 8:00 AM EST - 1 year ago

Immutep Quarterly Activities Report Q2 FY24

First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer

Jan 4, 2024, 8:00 AM EST - 1 year ago

First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer

Immutep: Upcoming Signals For 2024 (Maintain Buy)

Jan 3, 2024, 5:04 PM EST - 1 year ago

Immutep: Upcoming Signals For 2024 (Maintain Buy)

Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Dec 21, 2023, 8:00 AM EST - 1 year ago

Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Receives A$2.6 million R&D Tax Incentive from French Government

Dec 7, 2023, 8:00 AM EST - 1 year ago

Immutep Receives A$2.6 million R&D Tax Incentive from French Government

Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial

Nov 22, 2023, 8:00 AM EST - 1 year ago

Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial

Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Nov 9, 2023, 8:00 AM EST - 1 year ago

Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer

Nov 6, 2023, 8:00 AM EST - 1 year ago

Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer

Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer

Nov 3, 2023, 12:00 PM EDT - 1 year ago

Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer

Immutep to Participate in November Investor Events

Nov 2, 2023, 8:00 AM EDT - 1 year ago

Immutep to Participate in November Investor Events

Immutep Quarterly Activities Report Q1 FY24

Oct 31, 2023, 8:00 AM EDT - 1 year ago

Immutep Quarterly Activities Report Q1 FY24

Immutep receives ~A$1.13 million R&D Tax Incentive

Oct 25, 2023, 8:00 AM EDT - 1 year ago

Immutep receives ~A$1.13 million R&D Tax Incentive

Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023

Oct 24, 2023, 8:00 AM EDT - 1 year ago

Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023

Immutep's Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer

Oct 23, 2023, 8:00 AM EDT - 1 year ago

Immutep's Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer

Immutep Announces Publication of Abstracts at ESMO Congress 2023

Oct 16, 2023, 8:00 AM EDT - 1 year ago

Immutep Announces Publication of Abstracts at ESMO Congress 2023

Immutep Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Oct 3, 2023, 8:00 AM EDT - 1 year ago

Immutep Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use

Sep 21, 2023, 8:00 AM EDT - 1 year ago

Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use

Immutep to Participate in September Investor Conferences

Sep 5, 2023, 9:00 AM EDT - 2 years ago

Immutep to Participate in September Investor Conferences

Immutep: Nipping At The Heels Of LAG3.Is It Impressive Enough?

Sep 1, 2023, 6:57 PM EDT - 2 years ago

Immutep: Nipping At The Heels Of LAG3.Is It Impressive Enough?

Immutep Receives Positive Scientific Advice from European Medicines Agency

Aug 1, 2023, 8:00 AM EDT - 2 years ago

Immutep Receives Positive Scientific Advice from European Medicines Agency

IFeelLike
IFeelLike Jul. 15 at 9:04 PM
$IMMP nice, as Marc says, tacti004, if succesfull will enter a market worth 24 billion dollars, and is expected to increase the company value between 10-30x. As said before, will sell my first 1k reaching 30 dollars. Staying patient.
0 · Reply
IFeelLike
IFeelLike Jul. 15 at 8:58 PM
$IMMP
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jul. 15 at 8:32 PM
$IMMP resigns?? No 👎 of course … “Great “ trend from years Disappointed
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jul. 15 at 8:02 PM
$IMMP $JSPR shareholders are Waiting for massive resigns !!
0 · Reply
usera123
usera123 Jul. 15 at 7:50 PM
$IMMP Seeing new bozos arriving. 10 bucks says they're gone in a month, we longs know what too expect here. Nothing at all. The enthusiasm they show will fade along with their positions. Do yourselves a favor new arrivals and sell now. The permabulls are full of shit, as is the BoD and especially the CEO.
1 · Reply
Messerschmittbf109
Messerschmittbf109 Jul. 15 at 6:53 PM
$JSPR $IMMP These board .. awful board Must go home !
0 · Reply
NOCKNOCK
NOCKNOCK Jul. 15 at 6:44 PM
$IMMP suck um up! Ladies and Gentlemen. 😘🤙
0 · Reply
Messerschmittbf109
Messerschmittbf109 Jul. 15 at 2:42 PM
$JSPR all bio up except these $NGNE $INKT $IMMP $JSPR Jasper the worst ..and all board is on the chair 🤮
0 · Reply
Biotechnicity
Biotechnicity Jul. 15 at 1:09 PM
$IMMP This will rise steadily over the next three months or so. An active equity is on the way. Just watch!
1 · Reply
rispi
rispi Jul. 14 at 7:52 PM
$IMMP Last poor fireworks before next offering.
2 · Reply
Messerschmittbf109
Messerschmittbf109 Jul. 14 at 7:38 PM
$JSPR $IMMP …..are dead bio stocks
0 · Reply
rispi
rispi Jul. 14 at 6:19 PM
$IMMP Self produced video on a company’s YouTube channel with less than 200 watchers and the SP moved so greeen????
1 · Reply
Biotechnicity
Biotechnicity Jul. 14 at 5:42 PM
$IMMP started a position today.
1 · Reply
SeatownGreen
SeatownGreen Jul. 14 at 1:54 PM
$IMMP I have many concerns, but watching this 2 big ones. A) June discussions regarding HNSCC with FDA haven’t happened? B) Marc is in Australia and I’m extremely concerned he yet again failed to leverage assets for non-dilutive financing. He comes from the capital markets and will hit up friends like he’s always done. The stock will be halted for days while shareholders are diluted at desperate lows.
1 · Reply
Jimih717917
Jimih717917 Jul. 14 at 10:15 AM
$IMMP Enough of these cringe worthy setup videos. Release the data and get the SP to increase! https://youtu.be/tAm1bqiFKO8?si
1 · Reply
brad97
brad97 Jul. 14 at 3:24 AM
$IMMP https://youtu.be/tAm1bqiFKO8?si=NyFLsJABu91EgPup
1 · Reply
Biotechnicity
Biotechnicity Jul. 11 at 2:37 AM
$IMMP Under watch. Am reading your posts to understand the proposition and determine an entry. Thanks in advance!
1 · Reply
rispi
rispi Jul. 10 at 8:08 PM
$IMMP
0 · Reply
NOCKNOCK
NOCKNOCK Jul. 10 at 7:54 PM
$IMMP I read post below and I believe... Myslowandsteadyaccumulationwillmakecertainofit.🤣🤑
0 · Reply
bylocehi
bylocehi Jul. 10 at 7:34 PM
$IMMP see the post below. Therewasalargeamountofshortsellinglastyearinanticipationofanotherdilution.Thatdoesn’tlooklikeit’sgoingtohappen.Ithinkshortsmaybeatriskforasqueezeasdaily trade.Volumesaretoolowforthemto recovertheirpositions.
0 · Reply
TheIrishCzar
TheIrishCzar Jul. 10 at 4:41 PM
$IMMP looks like HNSCC may not give the early launch I was hoping for. It’s back burner to nsclc https://firstwordpharma.com/story/5980257
2 · Reply
SeatownGreen
SeatownGreen Jul. 10 at 3:56 PM
$IMMP Wonder how TACTI-004 enrollment is going? I wonder about potential suitors regarding business development? Non-dilutive financing is possible, can they pull it off?
0 · Reply